PharmaResearch Co., Ltd. (KOSDAQ:214450)

South Korea · Delayed Price · Currency is KRW

239,500

-15,500 (-6.08%)

Oct 23, 2026, 3:30 PM KST

Market Cap	2.49T -57.5%
Revenue (ttm)	603.58B +34.2%
Net Income	185.69B +46.2%
EPS	16,711.23 +39.2%
Shares Out	10.39M
PE Ratio	14.33
Forward PE	11.02
Dividend	3,700.00 (1.55%)
Ex-Dividend Date	Dec 29, 2025

Volume	139,459
Open	247,500
Previous Close	255,000
Day's Range	232,500 - 249,000
52-Week Range	232,500 - 578,000
Beta	0.47
Analysts	Strong Buy
Price Target	509,428.57 (+112.71%)
Est. Earnings	Nov 11, 2026

About PharmaResearch

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults thro... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1993

Employees 550

Stock Exchange KOSDAQ

Ticker Symbol 214450

Full Company Profile

Financial Performance

In 2025, PharmaResearch's revenue was 536.29 billion, an increase of 53.18% compared to the previous year's 350.12 billion. Earnings were 165.12 billion, an increase of 79.39%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for 214450 stock is "Strong Buy." The 12-month stock price target is ₩509,429, which is an increase of 112.71% from the latest price.

Price Target

₩509,429

(112.71% upside)

Analyst Consensus: Strong Buy

Stock Forecasts